英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
receptum查看　receptum　在百度字典中的解释百度英翻中〔查看〕
receptum查看　receptum　在Google字典中的解释Google英翻中〔查看〕
receptum查看　receptum　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Vyndamax for Transthyretin Amyloid Cardiomyopathy - WebMD
    Vyndamax was the first once-daily medicine for ATTR-CM that helps slow the progression of the disease and improve your quality of life How Vyndamax Works There are two types of ATTR-CM (see table
  • What is ATTR-CM? | VYNDAMAX® (tafamidis) | Safety Info
    Understand that ATTR-CM is a rare, life-threatening, progressive heart condition, which means it will get worse over time; Discuss treatment options with your doctor as soon as your diagnosis is confirmed The sooner you start treatment, the sooner you can begin to slow disease progression; It can be helpful to connect with other people
  • Vyndamax for Transthyretin Amyloid Cardiomyopathy - HealthCentral
    Vyndamax was approved by the U S Food and Drug Administration in 2019 as a treatment for a form of heart disease called transthyretin amyloid cardiomyopathy (ATTR-CM) Cardiomyopathies are
  • Vyndamax: Uses, Dosage, Side Effects Warnings - Drugs. com
    Vyndamax works by stabilizing abnormal transthyretin, a protein associated with ATTR-CM This mechanism of action of Vyndamax prevents the formation of harmful amyloid protein deposits in the heart, slowing disease progression Vyndamax was FDA approved on May 3, 2019 There is no Vyndamax generic Vyndaqel Vs Vyndamax
  • FDA approves new treatments for heart disease caused by a serious rare . . .
    These are the first FDA-approved treatments for ATTR-CM Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their
  • Transthyretin Amyloidosis (ATTR-CM): Types, Causes, Treatment
    Cardiomyopathy (CM) is a disease of your heart muscle (myocardium) TTR deposits in your heart muscle, leading to thickening and stiffening of your heart (ATTR-CM) can lead to heart failure and atrial fibrillation (Afib), Vyndamax®) and diflunisal (Dolobid®), a nonsteroidal anti-inflammatory drug (NSAID) that providers may use as an
  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - American Heart Association
    Transthyretin (trans-thy-re-tin) amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease of the heart muscle In ATTR-CM, a protein called transthyretin that normally circulates in the bloodstream becomes misshapen and builds up in the heart, nerves and other organs
  • U. S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in . . . - Pfizer
    “ATTR-CM is not only fatal, but also significantly underdiagnosed, with some patients cycling through multiple doctors and a myriad of tests over a period of years while the disease progresses,” said Isabelle Lousada, Founder and CEO, Amyloidosis Research Consortium “ATTR-CM is a rare disease for which more education and awareness is needed
  • About ATTR Cardiac Amyloidosis | VYNDAMAX (tafamidis) | Safety Info
    Disease Impact If you have patients with HFpEF, they may have transthyretin cardiac amyloidosis 1* *Also known as transthyretin amyloid cardiomyopathy (ATTR-CM) ATTR cardiac amyloidosis may be underdiagnosed in patients with HFpEF due to the 2 conditions’ similar clinical characteristics 1,2 ~1 in 10 patients over the age of 60 with HFpEF were found to have ATTR cardiac amyloidosis 3,4†
  • Vyndamax (Tafamidis) - Rare Disease Advisor
    Vyndamax ® (tafamidis) is an oral therapy developed by Pfizer that is indicated for the treatment of cardiomyopathy in adults with wild-type or hereditary transthyretin amyloidosis (hATTR) to reduce cardiovascular mortality and hospitalization 1 Initial approval of Vyndamax for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) was granted by the US Food and Drug Administration (FDA) in





中文字典-英文字典  2005-2009